封面
市場調查報告書
商品編碼
1563392

微型RNA市場規模、佔有率、成長分析(按產品/服務、按應用、按最終用途、按地區)- 行業預測,2024-2031 年

MicroRNA Market Size, Share, Growth Analysis, By Products & Services, By Application, By End-use, By Region - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2022年全球微型RNA市場規模將為12億美元,從2023年的13.5億美元成長到2031年的35.8億美元,預測期(2024-2031)預計複合年成長率為12.90%。

近年來,在分子生物學、基因組學和生物資訊學進步的推動下,全球微型RNA市場出現了顯著成長。 微型RNA(miRNA) 是調節基因表現所必需的小非編碼 RNA 分子,已被定位為各種疾病的有價值的生物標記和新治療方法的潛在目標。 miRNA 在診斷和治療方面的潛力,以及對其在疾病過程中作用的更好理解,是市場擴張的主要驅動力。癌症、心血管疾病和神經系統疾病等慢性疾病的增加導致了該領域研究和投資的增加,因為 miRNA 在疾病診斷、預後和治療方面具有廣闊的前景,進一步推動了這一成長。此外,次世代定序和微陣列平台等技術進步正在增強 miRNA 分析和檢測,支持市場開拓。然而,市場面臨一些挑戰。基於 miRNA 的治療和診斷的複雜監管環境是一個主要障礙,需要嚴格的要求和昂貴的臨床試驗。確保基於 miRNA 的產品的安全性、有效性和特異性至關重要,但也充滿挑戰。由於對 miRNA 功能和生物系統內相互作用的了解有限,研究也變得複雜。由於需要標靶遞送和穩定性,開發 miRNA 療法的有效遞送系統也是一個挑戰。儘管存在這些障礙,全球微型RNA市場仍存在巨大的成長和創新機會,技術進步、研究的增加以及有助於開發新的基於 miRNA 的診斷和治療方法的合作預計將得到促進。

目錄

介紹

  • 研究目的
  • 定義
  • 市場範圍

調查方法

  • 資訊採購
  • 次要/一級資訊來源
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 市場概況展望
  • 供需趨勢分析
  • 按細分市場的機會分析

市場動態及展望

  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務
  • 波特的分析

主要市場考察

  • 技術分析
  • 市場生態系統
  • 供應鏈分析
  • 案例研究分析
  • PESTLE分析
  • 監管環境
  • 創新矩陣
  • 重點投資分析
  • 關鍵成功因素
  • 競爭程度

微型RNA市場:依產品/服務分類

  • 市場概況
  • 服務
    • 類型
    • 分離/精製
    • miRNA cDNA 合成
    • 分析、本地化和量化
    • 泛函分析
    • 其他
    • 檢體
    • 全血
    • 血清
    • 電漿
    • FFPE
    • 新鮮冷凍組織
    • 其他
  • 產品
    • 裝置
    • 科技
    • 即時PCR
    • 微陣列
    • 下一代種子
    • 其他
    • 工作流程
    • 分離/精製
    • miRNA cDNA 合成
    • 分析、本地化和量化
    • 泛函分析等
    • 其他
    • 消耗品
    • 檢體
    • 工作流程
    • 分離/精製
    • miRNA cDNA 合成
    • 分析、本地化和量化
    • 泛函分析等
    • 其他
    • 全血
    • 血清
    • 電漿
    • FFPE
    • 新鮮冷凍組織
    • 其他

微型RNA市場:依應用分類

  • 市場概況
  • 癌症
  • 感染疾病
  • 免疫疾病
  • 心血管疾病
  • 神經系統疾病
  • 其他

微型RNA市場:依最終用途分類

  • 市場概況
  • 生技/製藥公司
  • 學術機構/政府研究機構
  • 其他

微型RNA市場規模:按地區分類

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東和非洲 (MEA)
    • 海灣合作理事會國家
    • 南非
    • 其他中東/非洲地區

競爭格局

  • 前5名企業對比
  • 主要企業市場定位(2023年)
  • 主要市場參與者所採取的策略
  • 近期市集活動
  • 主要企業市場佔有率(2023年)

主要企業簡介

  • Thermo Fisher Scientific, Inc.(US)
  • QIAGEN(Germany)
  • NanoString Technologies, Inc.(US)
  • Merck KGaA(Germany)
  • Takara Bio, Inc.(Japan)
  • BioGenex(US)
  • GeneCopoeia, Inc.(US)
  • New England Biolabs(US)
  • Agilent Technologies, Inc.(US)
  • Illumina, Inc.(US)
  • Abcam plc(UK)
  • Roche Holding AG(Switzerland)
  • Arcturus Therapeutics Ltd.(US)
  • Synthego Corporation(US)
  • Bio-Techne Corporation(US)
  • F. Hoffmann-La Roche Ltd.(Switzerland)
  • Asuragen, Inc.(US)
  • Cell Signaling Technology, Inc.(US)
  • Molecular Cloud(China)
  • Ribomed Biotechnologies, Inc.(US)
  • Sirnaomics Inc.(US)
簡介目錄
Product Code: SQMIG35H2216

Global MicroRNA Market size was valued at USD 1.20 billion in 2022 and is poised to grow from USD 1.35 billion in 2023 to USD 3.58 billion by 2031, growing at a CAGR of 12.90% during the forecast period (2024-2031).

The global microRNA market has experienced notable growth recently, fueled by advances in molecular biology, genomics, and bioinformatics. MicroRNAs (miRNAs) are small non-coding RNA molecules essential for regulating gene expression, positioning them as valuable biomarkers for various diseases and potential targets for new therapies. Increased understanding of miRNA's role in disease processes, alongside its potential in diagnostics and treatments, has significantly driven market expansion. The rise in chronic diseases, such as cancer, cardiovascular conditions, and neurological disorders, further supports this growth, as miRNAs show promise in disease diagnosis, prognosis, and treatment, leading to more research and investment in the field. Additionally, advancements in technologies like next-generation sequencing and microarray platforms have enhanced miRNA profiling and detection, boosting market development. However, the market faces several challenges. Navigating the complex regulatory landscape for miRNA-based therapeutics and diagnostics is a major hurdle, with stringent requirements and costly clinical trials. Ensuring the safety, efficacy, and specificity of miRNA-based products is critical but challenging. Limited understanding of miRNA functions and their interactions within biological systems also complicates research. Developing effective delivery systems for miRNA therapeutics is another challenge due to the need for targeted delivery and stability. Despite these obstacles, the global microRNA market holds substantial opportunities for growth and innovation, with technological advancements, increased research, and collaborative efforts expected to drive the development of new miRNA-based diagnostics and treatments.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global MicroRNA market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global MicroRNA Market Segmental Analysis

Global MicroRNA Market is segmented by Products & Services, Application, End-use, and region. Based on Products & Services, the market is segmented into services, and products. Based on Application, the market is segmented into Cancer, Infectious Diseases, Immunological Disorder, Cardiovascular Disease, Neurological Disease, and Others. Based on End-use, the market is segmented into Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global MicroRNA Market

Recent technological strides in genomics and molecular biology, particularly through next-generation sequencing and microarray platforms, have revolutionized the analysis of microRNAs. These advanced tools facilitate high-throughput examination, allowing researchers to identify and characterize microRNAs with greater efficiency. As a result, the capabilities of these technologies have spurred a surge in research activities, significantly contributing to the expansion of the microRNA market. The enhanced ability to analyze microRNAs has opened new avenues for discovery and innovation, further propelling market growth.

Restraints in the Global MicroRNA Market

Despite extensive research on microRNAs, their exact functions and mechanisms remain incompletely understood. This gap in knowledge presents challenges in pinpointing reliable and specific biomarkers, as well as in creating effective therapeutic strategies. The ongoing uncertainty surrounding microRNA biology complicates efforts to develop precise diagnostic and treatment options. Addressing these gaps is crucial for advancing the field and fully leveraging the potential of microRNAs in clinical applications.

Market Trends of the Global MicroRNA Market

Partnerships among biotechnology and pharmaceutical companies, academic research institutions, and government agencies are becoming more prevalent in the field of microRNA research. These collaborations combine the expertise, resources, and insights of various stakeholders, aiming to expedite the development and market introduction of microRNA-based products and solutions. By pooling their strengths, these collaborative efforts enhance the efficiency of research and development processes, driving innovation and accelerating the advancement of microRNA technologies. This collective approach supports the rapid commercialization and broader application of microRNA-based advancements.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Technology Analysis
  • Ecosystem of the Market
  • Supply chain Analysis
  • Case study Analysis
  • PESTLE Analysis
  • Regulatory Landscape
  • Innovation Matrix
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

MicroRNA Market by Products & Services

  • Market Overview
  • Services
    • Type
    • Isolation & Purification
    • miRNA cDNA Synthesis
    • Profiling, Localization, & Quantification
    • Functional Analysis
    • Others
    • Specimen
    • Whole Blood
    • Serum
    • Plasma
    • FFPE
    • Fresh Frozen Tissue
    • Others
  • Products
    • Instruments
    • Technology
    • Real Time PCR
    • Microarray
    • NGS
    • Others
    • Workflow
    • Isolation & Purification
    • miRNA cDNA Synthesis
    • Profiling, Localization, & Quantification
    • Functional Analysis & Others
    • Others
    • Consumables
    • Specimen
    • Workflow
    • Isolation & Purification
    • miRNA cDNA Synthesis
    • Profiling, Localization, & Quantification
    • Functional Analysis & Others
    • Others
    • Whole Blood
    • Serum
    • Plasma
    • FFPE
    • Fresh Frozen Tissue
    • Others

MicroRNA Market by Application

  • Market Overview
  • Cancer
  • Infectious Diseases
  • Immunological Disorder
  • Cardiovascular Disease
  • Neurological Disease
  • Others

MicroRNA Market by End-use

  • Market Overview
  • Biotechnology & Pharmaceutical Companies
  • Academic & Government Research Institutes
  • Others

MicroRNA Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Thermo Fisher Scientific, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • QIAGEN (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • NanoString Technologies, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck KGaA (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takara Bio, Inc. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioGenex (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GeneCopoeia, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • New England Biolabs (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Agilent Technologies, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Illumina, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Abcam plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Holding AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Arcturus Therapeutics Ltd. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Synthego Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio-Techne Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche Ltd. (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Asuragen, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Cell Signaling Technology, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Molecular Cloud (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ribomed Biotechnologies, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sirnaomics Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments